A S X A N N O U N C E M E N T 19 November 2026 Registrational Phase III AMPLIFY trial: Follow-up assessments completed for all participants Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation...
Follow-up assessments completed in Phase III AMPLIFY trial
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Clarity Pharmaceuticals Ltd. has announced the completion of follow-up assessments for all participants in its Phase III AMPLIFY trial, which focuses on a diagnostic imaging agent for prostate cancer. Clarity has received Breakthrough Therapy designation from the US FDA for this product, highlighting its potential to significantly improve diagnostic outcomes. Topline data from the AMPLIFY trial is expected to be released in the first half of the following year, which will support applications for FDA approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Becoming a substantial holder
- First FDA Breakthrough Therapy designation in PSMA PET
- Ceasing to be a substantial holder
- Trading Halt
- Pause in Trading
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals